Real-World Comparison Assesses Mobocertinib in NSCLC With EGFR Exon 20

Latest in EGFR-positive NSCLC with exon 20 insertion mutationsПодробнее

Real world data and diagnostics in patients with NSCLC with EGFR exon 20 insertionsПодробнее

Current treatments and challenges for patients with EGFR exon 20 insertion-positive NSCLCПодробнее

WU-KONG1: sunvozertinib in NSCLC with EGFR exon 20 insertion mutationsПодробнее

Managing patients with EGFR exon 20 ins in NSCLC and EGFR TKI toxicityПодробнее

The evolving treatment landscape for NSCLC with EGFR exon 20 insertion mutationsПодробнее

NSCLC With EGFR Exon 20 Shows Benefit With Mobocertinib Over ChemotherapyПодробнее

Amivantamab and Mobocertinib for EGFR Exon-20 Disease - Lung Cancer Video LibraryПодробнее

ASCO 2021 Lung Recap: Amivantamab and Mobocertinib for EGFR Exon 20Подробнее

Emerging Treatments and Clinical Trials for EGFR Exon-20 - Lung Cancer Video LibraryПодробнее

Poziotinib in Treatment-Naïve NSCLC With HER2 Exon 20 MutationsПодробнее

Testing Methods to Discover EGFR Exon-20 Disease - Lung Cancer Video LibraryПодробнее

Amivantamab and Mobocertinib: Side Effects and Treatment Timing - Lung CancerПодробнее

Dr. Horn on the Role of Mobocertinib in NSCLCПодробнее

Efficacy of mobocertinib in patients previously treated with TKIsПодробнее

EGFR Exon-20 Mutation - Lung Cancer Video LibraryПодробнее

From clinic to practice in NSCLC patients with exon 20 mutationsПодробнее

Treating Non–Small Cell Lung Cancer With an EGFR Exon 20 InsertionПодробнее

Targeted treatments for EGFR exon 20 insertion mutations in NSCLCПодробнее